Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.

Hsieh MH, Gu SL, Ho SC, Pawlak CR, Lin CL, Ho YJ, Lai TJ, Wu FY.

Behav Brain Res. 2012 Apr 1;229(1):41-7. doi: 10.1016/j.bbr.2011.12.035. Epub 2012 Jan 2.

PMID:
22227506
2.

Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.

Ho SC, Hsu CC, Pawlak CR, Tikhonova MA, Lai TJ, Amstislavskaya TG, Ho YJ.

Behav Brain Res. 2014 Jul 15;268:177-84. doi: 10.1016/j.bbr.2014.04.022. Epub 2014 Apr 19.

PMID:
24755306
3.

Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia.

Ho YJ, Ho SC, Pawlak CR, Yeh KY.

Behav Brain Res. 2011 Jun 1;219(2):280-90. doi: 10.1016/j.bbr.2011.01.028. Epub 2011 Jan 22.

PMID:
21262271
4.

Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in Wistar rats.

Wang AL, Liou YM, Pawlak CR, Ho YJ.

Behav Brain Res. 2010 Mar 17;208(1):38-46. doi: 10.1016/j.bbr.2009.11.006. Epub 2009 Nov 10.

PMID:
19900486
5.

The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.

Curr Pharm Des. 2011;17(5):489-507. Review.

PMID:
21375482
6.

Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia.

Hsu CY, Hung CS, Chang HM, Liao WC, Ho SC, Ho YJ.

Neuropharmacology. 2015 Apr;91:43-56. doi: 10.1016/j.neuropharm.2014.11.023. Epub 2014 Dec 10.

PMID:
25499022
7.

MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats.

Wang WF, Wu SL, Liou YM, Wang AL, Pawlak CR, Ho YJ.

Behav Neurosci. 2009 Dec;123(6):1261-70. doi: 10.1037/a0017401.

PMID:
20001109
8.

Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model.

Hsieh MH, Ho SC, Yeh KY, Pawlak CR, Chang HM, Ho YJ, Lai TJ, Wu FY.

Pharmacol Biochem Behav. 2012 Jul;102(1):64-71. doi: 10.1016/j.pbb.2012.03.022. Epub 2012 Mar 31.

PMID:
22487770
9.

Social odor recognition: a novel behavioral model for cognitive dysfunction in Parkinson's disease.

Monaghan MM, Leddy L, Sung ML, Albinson K, Kubek K, Pangalos MN, Reinhart PH, Zaleska MM, Comery TA.

Neurodegener Dis. 2010;7(1-3):153-9. doi: 10.1159/000289227. Epub 2010 Mar 3.

PMID:
20197696
10.

Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson's disease dementia.

Hsieh MH, Meng WY, Liao WC, Weng JC, Li HH, Su HL, Lin CL, Hung CS, Ho YJ.

Brain Res Bull. 2017 Jun;132:129-138. doi: 10.1016/j.brainresbull.2017.05.015. Epub 2017 May 30.

PMID:
28576659
11.

MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus.

Sy HN, Wu SL, Wang WF, Chen CH, Huang YT, Liou YM, Chiou CS, Pawlak CR, Ho YJ.

Pharmacol Biochem Behav. 2010 Apr;95(2):158-65. doi: 10.1016/j.pbb.2009.12.020. Epub 2010 Jan 11.

PMID:
20064549
12.

Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.

Castro AA, Wiemes BP, Matheus FC, Lapa FR, Viola GG, Santos AR, Tasca CI, Prediger RD.

Brain Res. 2013 Jun 4;1513:103-16. doi: 10.1016/j.brainres.2013.03.029. Epub 2013 Mar 30.

13.

SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.

Ago Y, Kawasaki T, Nashida T, Ota Y, Cong Y, Kitamoto M, Takahashi T, Takuma K, Matsuda T.

Neuropharmacology. 2011 Dec;61(8):1441-51. doi: 10.1016/j.neuropharm.2011.08.041. Epub 2011 Sep 2.

PMID:
21903118
14.

Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson's disease rat model: An immunohistochemical and MRI study.

Weng JC, Tikhonova MA, Chen JH, Shen MS, Meng WY, Chang YT, Chen KH, Liang KC, Hung CS, Amstislavskaya TG, Ho YJ.

Behav Brain Res. 2016 May 15;305:126-39. doi: 10.1016/j.bbr.2016.02.034. Epub 2016 Mar 3.

PMID:
26940602
15.

Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease.

Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD.

Behav Brain Res. 2012 Apr 1;229(1):208-15. doi: 10.1016/j.bbr.2012.01.016. Epub 2012 Jan 17.

PMID:
22266923
16.

Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Matheus FC, Aguiar AS Jr, Castro AA, Villarinho JG, Ferreira J, Figueiredo CP, Walz R, Santos AR, Tasca CI, Prediger RD.

Behav Brain Res. 2012 Dec 1;235(2):263-72. doi: 10.1016/j.bbr.2012.08.017. Epub 2012 Aug 17.

PMID:
22921927
17.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
19.

Measuring attention in a Parkinson's disease rat model using the 5-arm maze test.

Ho SC, Hsu CC, Yu CH, Huang WN, Tikhonova MA, Ho MC, Hung CS, Amstislavskaya TG, Ho YJ.

Physiol Behav. 2014 May 10;130:176-81. doi: 10.1016/j.physbeh.2014.03.017. Epub 2014 Mar 30.

PMID:
24690450
20.

Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.

Reksidler AB, Lima MM, Dombrowski P, Andersen ML, Zanata SM, Andreatini R, Tufik S, Vital MA.

J Neurosci Methods. 2008 Jan 30;167(2):268-77. Epub 2007 Sep 5.

PMID:
17931705

Supplemental Content

Support Center